Therapeutic options in androgen-independent prostate cancer: building on docetaxel

Area of Science:

• Oncology
• Urology
• Medical Oncology

Background:

• Metastatic prostate cancer often becomes androgen-independent after initial response to androgen ablation.
• Hormone-refractory prostate cancer (HRPCa) historically had limited treatment options with no survival benefit.
• Mitoxantrone and prednisone offered palliation but not improved survival for HRPCa.

Purpose of the Study:

• To evaluate the survival benefit of docetaxel-based chemotherapy compared to standard care in HRPCa.
• To explore novel therapeutic strategies targeting angiogenesis, apoptosis, and signal transduction in HRPCa.
• To refine definitions of response, eligibility criteria, and surrogate markers for HRPCa clinical trials.

Main Methods:

• Two large randomized trials involving over 1700 patients were conducted.
• Patients received either mitoxantrone-based therapy or docetaxel-based therapy.
• Ongoing phase I and II studies are investigating novel drug combinations.

Main Results:

• Docetaxel-based therapy demonstrated a survival benefit in HRPCa patients.
• Docetaxel-based therapy reduced the risk of death by 20-24% compared to mitoxantrone-based therapy.
• Novel combinations show promising activity in early-phase studies.

Conclusions:

• Docetaxel-based chemotherapy is a superior treatment option for metastatic prostate cancer progression.
• Future research focuses on improving docetaxel efficacy with targeted agents.
• Refinement of clinical trial methodologies is crucial for advancing HRPCa treatment.